Amanote Research
Register
Sign In
Indolenter Lymphome: Bendamustin Plus Rituximab in Der Firstline
Info Onkologie
doi 10.1007/bf03363083
Full Text
Open PDF
Abstract
Available in
full text
Date
October 1, 2011
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Merkelzell-Karzinome - Eine Differenzialdiagnose Der Lymphome in Der Haut
Aktuelle Dermatologie
Dermatology
Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Fludarabine Plus Cyclophosphamide and Rituximab in Waldenstrom Macroglobulinemia
Cancer
Cancer Research
Oncology
Rituximab Ist Wesentlicher Bestandteil Der Therapie
Best Practice Onkologie
Oncology
Rituximab Plus ABVD in Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma
British Journal of Haematology
Hematology
Deutsche Studiengruppe Niedrigmaligne Lymphome
Info Onkologie
Non-Hodgkin-Lymphome
Onkologe
Oncology
Hematology
Rituximab Alone (R) Versus Rituximab Plus Bendamustine (Br) for Splenic (Smzl) and Nodal Marginal Zone Lymphoma (Nmzl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-Cvad Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
